Lv3
220 积分 2022-02-14 加入
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer
6个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
6个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
7个月前
已完结
皖公网安备34019202002308
